Federal regulators are going to consider allowing compounding of some peptides, after Health Secretary Robert F. Kennedy Jr. described himself as a big fan of the substances.
The Food and Drug Administration has scheduled meetings on July 23 and July 24 on whether to allow compounding of BPC-157 for chronic bowel disease, KPV for inflammatory conditions, MOTs-C for obesity, and additional peptides for other issues, according to a notice filed on April 15.
The meetings will involve the FDA’s Pharmacy Compounding Advisory Committee, which has only four members at present and six vacancies.
Peptides are molecules that contain amino acids, and include approved products such as insulin as well as unapproved products….